Bisphosphonate therapy for hormone refractory prostate cancer with bone metastasis

Journal of Urology

Volumn 169, Issue 1, 2003, Pages 281-282

  Asahi, Hideki ^a   Mizokami, Atushi ^a   Maeda, Yuji ^a   Komatsu, Kazuto ^a   Koshida, Kiyoshi ^a   Namiki, Mikio ^a  

^a Yatsuo General Hospital   (Japan)

Author keywords

Bone neoplasms; Clodronic acid; Diphosphonates; Neoplasm metastasis; Prostatic neoplasms

Indexed keywords

ANTIANDROGEN; BISPHOSPHONIC ACID DERIVATIVE; CHLORMADINONE ACETATE; CLODRONIC ACID; ESTRAMUSTINE; GONADORELIN DERIVATIVE; INCADRONIC ACID; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; BONE CANCER; BONE METASTASIS; BONE PAIN; BONE SCINTISCANNING; CANCER HORMONE THERAPY; CASE REPORT; HUMAN; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE DISEASE;

EID: 0037213187     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)64093-1     Document Type: Article

References (3)

1. Heidenreich, A., Hofmann, R. and Engelmann, U. H.: The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer. J Urol, 165: 136, 2001
2. Lee, M. V., Fong, E. M., Singer, F. R. and Guenette, R. S.: Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res, 61: 2602, 2001
3. Senaratne, S. G., Mansi, J. L. and Colston, K. W.: The bisphosphonate zoledronic acid impairs membrane localisation and induces cytochrome c release in breast cancer cells. Br J Cancer, 86: 1479, 2002